APEEJAY SURRENDRA PARK Q1 FY26 Results

 APEEJAY SURRENDRA PARK | Q1 FY26 Results

• Consolidated Net Profit at ₹13.14 Cr vs loss of ₹1.88 Cr (YoY) | ↓ 50% QoQ

• Revenue ↑ 14% YoY at ₹154 Cr | ↓ 13% QoQ

• EBITDA ↑ 16% YoY at ₹45.39 Cr | ↓ 27% QoQ

• EBITDA Margin at 29.42% vs 29.03% (YoY) and 35.10% (QoQ)

RHI MAGNESITA Q1 update

 RHI MAGNESITA Q1 updates

NET PROFIT DOWN 52% AT 35.26 CR (YOY), DOWN 3% (QOQ)

REVENUE UP 9% AT 960 CR (YOY), UP 5% (QOQ)

EBITDA DOWN 34% AT 102 CR (YOY), UP 10% (QOQ)

MARGINS AT 10.64% V 17.51% (YOY), 10.14% (QOQ)

DIAMOND POWER Q1 update

 DIAMOND POWER Q1 : 

CONS NET PROFIT ↑ 21% AT 20.1 CR (YOY), ↑ 162% (QOQ)

REVENUE ↑ 36% AT 302 CR (YOY), ↓ 10% (QOQ)

EBITDA ↑ 29% AT 31 CR (YOY), ↑ 126% (QOQ)

MARGINS AT 10.3% ▼ FROM 10.75% (YOY), ▲ FROM 4.1% (QOQ)

PANACEA BIOTECH UPDATE

 PANACEA BIOTECH: ICMR Update on Dengue Vaccine & New Medical Device

Dengue Vaccine:
Developed by Panacea Biotec; Phase 3 trials underway with ICMR.
80% of 10,500 participants enrolled.
Results expected in ~2 years, potentially leading to market launch.

New Device:
Handheld infrared tool approved by DCGI & CDSCO.
Serves as an easy alternative to CT scans for detecting brain injury/bleeding.

Government Company having dividend yield greater than 5%